share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Feb 14 08:21
Summary by Moomoo AI
Cybin Inc., a biopharmaceutical company listed on the NYSE American LLC under the ticker CYBN, filed its Form 6-K with the SEC for February 2024, detailing its financial performance for the nine months ended December 31, 2023. The report, signed by CEO Doug Drysdale on February 14, 2024, includes unaudited condensed interim consolidated financial statements prepared in accordance with International Accounting Standards. Cybin reported a significant increase in total assets, from CAD 53,897 thousand as of March 31, 2023, to CAD 129,724 thousand as of December 31, 2023. The company's cash position improved markedly to CAD 38,999 thousand from CAD 16,633 thousand. However, Cybin also reported a net loss of CAD 56,734 thousand for the nine-month period, compared to a net loss of CAD 33,770 thousand for the same period in the previous...Show More
Cybin Inc., a biopharmaceutical company listed on the NYSE American LLC under the ticker CYBN, filed its Form 6-K with the SEC for February 2024, detailing its financial performance for the nine months ended December 31, 2023. The report, signed by CEO Doug Drysdale on February 14, 2024, includes unaudited condensed interim consolidated financial statements prepared in accordance with International Accounting Standards. Cybin reported a significant increase in total assets, from CAD 53,897 thousand as of March 31, 2023, to CAD 129,724 thousand as of December 31, 2023. The company's cash position improved markedly to CAD 38,999 thousand from CAD 16,633 thousand. However, Cybin also reported a net loss of CAD 56,734 thousand for the nine-month period, compared to a net loss of CAD 33,770 thousand for the same period in the previous year. The company's shareholders' equity increased to CAD 121,221 thousand from CAD 48,234 thousand. Cybin's financial statements were approved by the board of directors and include the acquisition of Small Pharma Inc., which became a wholly-owned subsidiary on October 23, 2023. The acquisition added goodwill of CAD 11,872 thousand and significantly bolstered Cybin's intangible assets. Cybin's common shares are also traded on Cboe Canada and quoted on the Frankfurt Stock Exchange.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more